(AOF) – Euroapi has announced the acquisition of BianoGMP, a Contract and Development Manufacturing Organization (CDMO) company with recognized expertise in oligonucleotides, for a total amount of approximately 10 million euros. The latter includes the acquisition price (initial payment and deferred amount) and industrial investments intended to increase Biano’s capacities and enable it to carry out larger-scale and more complex projects.
The closing of the transaction is subject to customary conditions and is expected in the fourth quarter of 2023. It will have limited impacts on the financial performance of the active pharmaceutical ingredients specialist in 2023.
“Oligonucleotides are large molecules with complex structures that lend themselves to various therapeutic applications, including the treatment of cancer, diseases of the central nervous system, genetic, infectious or metabolic diseases,” explains Euroapi. “The global oligonucleotide market is growing at 12% to 14% per year and is almost entirely outsourced to CDMOs.”
The extension of Euroapi’s capabilities in oligonucleotides, planned for its Frankfurt site in 2025, will complement Biano’s early-stage expertise and allow it to support larger-scale projects. Beyond the opportunities for commercial synergies via cross-references and scientific cooperation, this transaction will allow Euroapi to continue to differentiate itself to support a broader clientele, and this throughout the value chain of oligonucleotides, from research to commercialization.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
